Fractyl Health's Revita Study Meets Primary Endpoints for Post-GLP-1 Weight Maintenance

Key Facts

1Fractyl Health's REMAIN-1 pivotal study met its six-month co-primary endpoints with high statistical significance.

2Revita demonstrated 80% retention of GLP-1 induced weight loss versus 67% for the sham group.

Fractyl Health's REMAIN-1 pivotal study met its six-month co-primary endpoints with high statistical significance. GlobeNewswire reported that the Revita procedure demonstrated 80% retention of GLP-1 induced weight loss compared to 67% for the sham group following the discontinuation of drug therapy.

The study addresses the common clinical challenge of rapid weight regain once GLP-1 therapy is stopped by providing a non-drug procedural solution. GUTS closed at $4.16 on October 15, 2026, having traded between a session low of $3.92 and a high of $4.21.